

Information For the User
Telmisartan I.P. 40mg + Cilnidipine I.P. 10mg Tablets

Telbolife LN 40 Tablet

Description:

Telbolife LN 40 is a fixed-dose combination tablet containing Telmisartan, an angiotensin II receptor blocker (ARB), and Cilnidipine, a dihydropyridine calcium channel blocker with L-type and N-type calcium channel blocking properties. This combination is used to manage hypertension effectively and protect against cardiovascular risks.

Composition:

Each film-coated tablet contains:

Telmisartan I.P. 40 mg

Cilnidipine I.P. 10 mg

Excipients q.s.

Indications:

- Essential hypertension
- Hypertension with associated risk of cardiovascular events
- Hypertension not adequately controlled by monotherapy

Mechanism of Action:

Telmisartan blocks angiotensin II receptors, preventing vasoconstriction and aldosterone secretion, thereby lowering blood pressure.

Cilnidipine inhibits L-type and N-type calcium channels, resulting in vasodilation and suppression of sympathetic nerve activity, contributing to better blood pressure control.

Dosage and Administration:

One tablet once daily, or as directed by the physician. Dosage should be adjusted based on clinical response.

Side Effects:

- Dizziness
- Peripheral edema
- Hypotension
- Headache
- Flushing
- Palpitations
- Rare: Hyperkalemia, elevated liver enzymes

Precautions:

- Use with caution in patients with impaired hepatic or renal function
- Not recommended during pregnancy and lactation
- Monitor blood pressure and renal function periodically

- Avoid concomitant use with potassium-sparing diuretics or potassium supplements unless indicated

Storage:

Store in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for